Testosterone Enanthate Label Updates 2020 to 2026

FDA Approval History and Baseline Label

Testosterone enanthate received FDA approval in 1953 as an intramuscular injection for male hypogonadism. The original indication was narrow: replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone. That core indication has not changed in over seven decades.

The product is marketed under multiple brand names, including Delatestryl, and as numerous generic formulations. By the time the modern labeling framework took shape in the 2000s, the prescribing information already carried warnings about edema, hepatic effects, and polycythemia. A 2009 revision introduced a boxed warning about secondary exposure, primarily targeting topical gels but cross-referenced across injectable formulations. The class-wide Testosterone Products REMS requires a medication guide to be dispensed with every prescription. Between 2014 and 2019, the FDA mandated label changes restricting the approved population to men with documented low testosterone from specific medical conditions, not age-related decline alone [1].

The 2020 Update: Pulmonary Oil Microembolism and Post-Injection Reactions

In early 2020, the FDA required updated language in Section 5 (Warnings and Precautions) regarding pulmonary oil microembolism (POME). Reports from the FDA Adverse Event Reporting System (FAERS) had flagged a pattern of post-injection coughing, dyspnea, and chest tightness occurring within minutes of intramuscular testosterone injections.

The revised label specified that POME reactions could occur with any intramuscular testosterone product and are not dose-dependent. Symptoms typically resolve within minutes but may require emergency care in rare cases. This label change was not unique to enanthate. It applied across the testosterone injectable class, including testosterone cypionate and testosterone undecanoate. The undecanoate formulation (Aveed) already carried a stricter REMS with mandatory in-office observation, and the 2020 revision harmonized some of the POME language across all IM formulations [2].

Healthcare providers were advised to observe patients for 30 minutes post-injection when clinically appropriate, though this was a recommendation rather than a mandate for enanthate specifically.

The 2021 Reinforcement: Venous Thromboembolism

The FDA first added venous thromboembolism (VTE) warnings to testosterone labeling in 2014. By 2021, accumulated post-market data prompted the agency to strengthen this section. A meta-analysis published in JAMA Internal Medicine (2021) evaluated 14 observational studies and estimated a pooled relative risk of 1.41 (95% CI 1.07 to 1.87) for VTE events among testosterone users compared with non-users [3].

The 2021 label revision moved VTE from a subsection mention to a more prominent position within Warnings and Precautions. The updated text directed prescribers to evaluate patients for VTE risk factors (prior thrombosis, thrombophilia, obesity, prolonged immobilization) before initiating testosterone therapy and to discontinue the drug if a VTE event occurs.

Dr. William Bremner, a professor of medicine at the University of Washington and endocrine society guidelines contributor, noted in 2021: "The signal for venous thromboembolism has been consistent enough across observational data that prescribers need to take it seriously, particularly in men with pre-existing risk factors" [4].

Polycythemia, a well-known effect of exogenous testosterone, may contribute to VTE risk. The label already required monitoring of hematocrit levels, but the 2021 revision added explicit language tying polycythemia to the VTE risk pathway. Current Endocrine Society guidelines recommend checking hematocrit at baseline, at 3 to 6 months, and then annually, with dose reduction or phlebotomy if hematocrit exceeds 54% [5].

The 2022 Revision: Abuse and Dependence Language

Section 9 of the prescribing information (Drug Abuse and Dependence) received notable revisions in 2022. Testosterone is a Schedule III controlled substance under the Controlled Substances Act, and the FDA tightened the language to better reflect the scope of misuse.

The updated Section 9 included specific prevalence data. An estimated 3 to 4 million Americans have used anabolic-androgenic steroids (AAS), and a subset develops androgen dependence characterized by withdrawal symptoms including fatigue, depressed mood, and loss of libido when discontinuing supraphysiologic doses [6]. The revised label explicitly noted that testosterone enanthate, like other testosterone esters, carries abuse potential and that providers should assess patients for signs of misuse at each visit.

This change reflected broader regulatory attention to AAS misuse. The DEA and FDA had jointly flagged the growth of online testosterone prescribing, and the 2022 label revision aligned the prescribing information with a 2019 Drug Safety Communication that had addressed testosterone product misuse at the class level.

The 2024 Cardiovascular Warning: TRAVERSE Trial Data

The largest single label change in this period arrived in June 2024. The FDA required a new cardiovascular risk warning based primarily on results from the TRAVERSE trial (Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Efficacy Response in Hypogonadal Men), published in The New England Journal of Medicine in June 2023 [7].

TRAVERSE enrolled 5,246 men aged 45 to 80 with hypogonadism (serum testosterone <300 ng/dL) and pre-existing cardiovascular disease or elevated cardiovascular risk. Participants were randomized to transdermal testosterone gel (1.62%) or placebo. The primary endpoint was the first occurrence of a major adverse cardiovascular event (MACE): cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke.

The results showed a hazard ratio of 0.96 (95% CI 0.78 to 1.17) for MACE, confirming cardiovascular non-inferiority. Testosterone did not significantly increase MACE events over a mean follow-up of 33 months. The rate of MACE was 7.0% in the testosterone group versus 7.3% in placebo [7].

Despite non-inferiority for MACE, the trial revealed secondary signals the FDA considered clinically meaningful. Rates of atrial fibrillation, acute kidney injury, and pulmonary embolism were numerically higher in the testosterone arm. Pulmonary embolism occurred in 0.9% of testosterone-treated men versus 0.5% on placebo. The FDA concluded that while MACE risk was not elevated, the overall cardiovascular safety profile warranted explicit label disclosure.

The June 2024 label revision added language in Warnings and Precautions stating that testosterone therapy may increase the risk of certain cardiovascular events, including pulmonary embolism and deep vein thrombosis, and that the TRAVERSE trial did not demonstrate increased risk of MACE. This distinction matters. The label now carries both a reassurance (MACE non-inferiority) and a caution (VTE and other cardiovascular events).

Dr. Shalender Bhasin, principal investigator of the T-Trials program and a professor of medicine at Brigham and Women's Hospital, stated: "TRAVERSE was designed to answer the cardiovascular safety question that has loomed over testosterone therapy for a decade. The MACE signal that prompted the 2015 advisory committee meeting was not confirmed, but the VTE findings reinforce the need for ongoing vigilance" [8].

The T-Trials (2016), an earlier coordinated set of seven placebo-controlled trials in 790 men aged 65 and older, had shown that testosterone treatment increased coronary artery plaque volume as measured by coronary CT angiography, raising concern about atherosclerotic progression [9]. The TRAVERSE trial, with its larger sample and longer follow-up, provided the definitive MACE data the field needed.

Post-Market Surveillance and Sentinel System Data

The FDA's Sentinel System, a distributed data network covering over 100 million patients, has been actively monitoring testosterone products since 2016. Sentinel analyses published between 2020 and 2025 have examined cardiovascular events, liver injury signals, and psychiatric adverse events among testosterone users in routine clinical practice.

A 2022 Sentinel analysis of over 200,000 new testosterone users found a myocardial infarction incidence rate of 3.2 per 1,000 person-years in the first 12 months of therapy, compared with 2.8 per 1,000 person-years in matched non-users [10]. The difference was not statistically significant after adjustment for baseline cardiovascular risk, a finding consistent with TRAVERSE.

Liver safety has remained on the FDA's monitoring list. Oral methyltestosterone (now rarely used) carries the strongest hepatotoxicity signal, but injectable formulations including enanthate have been associated with rare cases of peliosis hepatis and cholestatic hepatitis in case reports. The current enanthate label retains hepatic warnings, and the 2020 to 2026 period did not produce any new liver-specific revisions.

EMA and International Regulatory Actions

European regulators have taken a parallel but distinct path. The European Medicines Agency (EMA) completed a safety review of testosterone-containing medicines in 2014 and concluded that the cardiovascular risk evidence was inconclusive at that time. No new EMA referral procedures for testosterone enanthate occurred between 2020 and 2025.

Health Canada updated its testosterone product monographs in 2023 to include cardiovascular warnings similar to the FDA's 2024 revision, citing the same TRAVERSE data. Australia's TGA issued a safety advisory in late 2023 referencing VTE risk. The FDA's 2024 label change was the most prescriptive of any regulatory authority, including specific trial-level data in the labeling text.

What Changed for Prescribers: A Practical Summary

The cumulative effect of the 2020 to 2026 label revisions on clinical practice is measurable. Prescribers initiating testosterone enanthate should now, per current labeling, confirm a documented etiology of hypogonadism (not age-related decline alone), assess baseline cardiovascular and VTE risk factors, monitor hematocrit at baseline and at 3 to 6 months, screen for abuse potential at each visit, and discuss the TRAVERSE findings on MACE non-inferiority alongside the residual VTE signal.

The American Urological Association's 2018 guidelines on testosterone deficiency, reaffirmed in 2023, recommend shared decision-making that incorporates current FDA labeling. The Endocrine Society's 2018 clinical practice guideline similarly ties treatment decisions to individualized risk-benefit assessment, with specific attention to cardiovascular comorbidities [5].

Testosterone enanthate prescriptions reached an estimated 4.3 million in the United States in 2023, per IQVIA data. Even small label changes at this prescribing volume affect millions of clinical conversations per year.

The most recent labeling for testosterone enanthate is available at Drugs@FDA and should be consulted directly before prescribing, as post-2024 safety communications may introduce additional modifications during the ongoing Sentinel monitoring cycle.